Table 1 Distribution of clinicopathologic and demographic factors in intermediate risk patients classified as good or poor prognosis by PAM model

N total

144

130

0.001

With extentions

32 % (47)

15 % (19)

N total

127

114

<0.001

with nodal involvement

65 % (83)

35 % (40)

N total

144

135

0.08

Stage 1

22 % (32)

22 % (30)

Stage 2

40 % (58)

52 % (70)

Stage 3

38 % (54)

26 % (35)

N total

179

142

<0.001

Classical

80 (144)

54 (77)

Follicular

5 (9)

44 (62)

Tall cell

15 (26)

2 (3)

N total

184

143

0.41

less than 45 years

50 (92)

45 (64)

N total

184

143

0.7834

Female

72 % (132)

76 % (108)

Male

28 % (52)

24 % (35)

N total

154

55

0.544

Asian

11 % (17)

14 % (8)

Black/African American (n)

7 % (11)

4 % (2)

White

82 % (126)

82 % (45)

Mutations

BRAF

N total

162

124

<0.001

With mutations

85 % (137)

21 % (26)

HRAS

N total

162

124

<0.001

With mutations

0 %

9 % (11)

KRAS

N total

162

124

0.36

With mutations

0 %

2 % (2)

NRAS

N total

162

124

<0.001

With mutations

2 % (4)

15 % (19)